A mouse study published in the European Journal of Pharmacology reports that the GLP-1 receptor agonist dulaglutide reduced markers of liver injury in a diabetic mouse model of metabolic dysfunction-associated steatotic liver disease. The authors say the findings support further investigation of the drug in MASLD, not that its use in the condition is established.

The work was carried out entirely in db/db mice, a strain used to model diabetes and fatty liver, and the abstract does not describe any human testing. Dulaglutide is a glucagon-like peptide-1 receptor agonist already approved for diabetes treatment, and MASLD is a chronic liver disease that the authors describe as spanning simple fat accumulation, steatohepatitis, fibrosis and cirrhosis.

Study overview

The researchers treated the db/db mouse model for 10 weeks and then assessed liver function, tissue histopathology, inflammation and fibrosis. They also measured ferroptosis-related markers and ran a lipidomics analysis of the animals' hepatic lipid profiles.

Ferroptosis is a form of cell death linked to iron accumulation and lipid peroxidation. The study was designed to test whether dulaglutide acted on that pathway in the liver.

Key results

The paper reports that dulaglutide reduced serum ALT and AST, two standard blood measures of liver injury, and altered expression of the ferroptosis-related proteins ACSL4 and GPX4. Reactive oxygen species staining and iron quantification indicated that treated animals showed less oxidative stress and less iron accumulation than untreated db/db mice.

Treatment was also associated with higher GSH and Nrf2 and lower MDA and 4-HNE, which the authors interpret as reduced lipid peroxidation. The lipidomics analysis showed what the paper calls extensive remodeling of the hepatic lipid profile, and inflammatory and fibrotic marker expression was reduced.

Limitations

This was an animal study in a single genetic mouse strain, and the abstract reports no human data. The published abstract also gives no group sizes, no dose and no effect sizes, so the magnitude of the changes cannot be judged from it.

Markers such as ALT, AST and GPX4 are surrogate measures rather than clinical outcomes, and improvement in them does not by itself establish a benefit for people with MASLD.

What it means

The authors conclude that dulaglutide modulates ferroptosis-related markers, inflammation and fibrosis in this model, and describe it as a potential therapeutic option for MASLD. Whether any of that carries into human liver disease remains untested in this paper.